Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.
The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.
However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.
Modi-3 may play a role
As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.
Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.
Last year four teams won financial backing from the charity.
Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint.
“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer.
“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."